Sign In
Buy LUCD
$1.01
-0.0250 (-2.43%)
At Close: Jun 03, 2026
PAVmed Provides Business Update and Reports First Quarter 2026 Financial Results
08:00am, Friday, 15'th May 2026
Veris Health progressed commercial expansion and advanced implantable physiological monitor development toward FDA submission Lucid Diagnostics continued building commercial momentum and strengthened
Lucid Diagnostics Inc. (LUCD) Q1 2026 Earnings Call Transcript
04:30pm, Thursday, 14'th May 2026
Lucid Diagnostics Inc. (LUCD) Q1 2026 Earnings Call Transcript
Lucid Diagnostics Q1 Earnings Call Highlights
01:10pm, Thursday, 14'th May 2026
Lucid Diagnostics NASDAQ: LUCD reported first-quarter 2026 EsoGuard test volume above its pre-Medicare target range, while management said it continues to await a Medicare local coverage determination
Lucid Diagnostics Inc. (LUCD) Reports Q1 Loss, Misses Revenue Estimates
10:25am, Thursday, 14'th May 2026
Lucid Diagnostics Inc. (LUCD) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to a loss of $0.16 per share a year ago.
Lucid Diagnostics Provides Business Update and Reports First Quarter 2026 Financial Results
08:00am, Thursday, 14'th May 2026
Processed 3,177 EsoGuard ® tests and recognized 1Q26 revenue of $1.3 million, ending quarter with $45 million in proforma cash and a runway that extends into 2027 and past upcoming reimbursement mile
Lucid Diagnostics Inc. (LUCD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
11:01am, Friday, 08'th May 2026
Lucid Diagnostics (LUCD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PAVmed to Hold First Quarter 2026 Business Update Conference Call and Webcast on May 15, 2026
08:31am, Friday, 01'st May 2026
Conference Call and Webcast at 8:30 AM ET NEW YORK, May 1, 2026 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, ope
Lucid Diagnostics to Hold First Quarter 2026 Business Update Conference Call and Webcast on May 14, 2026
08:31am, Thursday, 30'th Apr 2026
Conference Call and Webcast at 8:30 AM ET NEW YORK, April 30, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical d
Lucid Diagnostics Announces Closing of $18 Million Underwritten Offering of Common Stock
10:23am, Friday, 24'th Apr 2026
NEW YORK, April 24, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVme
Lucid Diagnostics Announces $18 Million Underwritten Offering of Common Stock
08:30am, Thursday, 23'rd Apr 2026
NEW YORK, April 23, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVme
Lucid Diagnostics Inc. (NASDAQ:LUCD) Receives Average Recommendation of “Moderate Buy” from Analysts
04:10am, Saturday, 18'th Apr 2026
Shares of Lucid Diagnostics Inc. (NASDAQ: LUCD - Get Free Report) have received an average recommendation of "Moderate Buy" from the five research firms that are covering the stock, MarketBeat reports
Lucid Diagnostics to Participate in Fireside Chat at the 25th Annual Needham Virtual Healthcare Conference
08:01am, Thursday, 09'th Apr 2026
NEW YORK, April 9, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVme
PAVmed Appoints Joseph Virgilio to Lead Relaunched Medical Device Portfolio
08:01am, Thursday, 02'nd Apr 2026
Medtech industry veteran to oversee development and commercialization of PAVmed's current and future medical device portfolio. Octeris, Inc. subsidiary formed to advance endoscopic esophageal imaging
PAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
08:00am, Monday, 30'th Mar 2026
PAVmed strengthened its capital structure and relaunched its medical device portfolio under new leadership Veris Health advanced strategic partnership with OSU and progressed implantable physiological
Lucid Diagnostics Q4 Earnings Call Highlights
01:02am, Saturday, 28'th Mar 2026
Lucid Diagnostics (NASDAQ: LUCD) reported higher fourth-quarter 2025 EsoGuard testing volume and revenue and highlighted progress on reimbursement initiatives, including a new U.S. Department of Veter
